Immutep (ASX:IMM), a company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, has announced what it describes as "encouraging final data" from its phase one INSIGHT-004 study. …
Latest Video
New Stories
-
Chimeric signals board refresh and shareholder support as lead trial advances
November 30, 2025 - - Australian Biotech -
Pharmac announces 90-day dispensed quantities of HIV medicines
November 27, 2025 - - Latest News -
Landmark report warns Australia’s hospital pharmacy system is at an 'inflection point'
November 27, 2025 - - Latest News -
Australia releases first national estimate of women living with metastatic breast cancer
November 27, 2025 - - Latest News -
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 - - Australian Biotech -
Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership
November 27, 2025 - - Latest News -
An interview that reminds us of the missing discussion in Australia
November 27, 2025 - - Latest News